BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 22, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exenatide once weekly regulatory update

FDA issued a complete response letter for an NDA from Amylin for Bydureon exenatide once weekly to treat Type II diabetes. According to the company, the letter primarily included requests related to the finalization of product labeling with a REMS and...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >